Skip to main content
S&P 5007,663.43-1.21%DOW52,867.98+0.02%NASDAQ26,008.86-2.60%BTC$81,323.00-3.23%ETH$2,386.40-3.43%GOLD$4,036.90-0.58%OIL$99.41-0.06%
Smart Investors Daily
SID Premium
MY

NYSE · MYE

Myers Industries, Inc.

Consumer Cyclical · Packaging & Containers

$32.89

Down-$0.06 (-0.18%)

Updated Oct 23, 2026, 12:03 AM

SID Score

6.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
738.43M
P/E ratio
26.44
Dividend yield
1.64%
52-week range
$16.46 – $37.45
Volume
308.5K
Avg. volume
254.87K

Price performance · MYE

MYE price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 21, 2026

MYE closed at $32.89 after 20 trading sessions, up 4.02% for the selected period.

Last close
$32.89
Period change
+4.02%
Period low
$30.04
Period high
$32.89
Daily close
View OHLC price history
MYE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 21, 2026$32.59$32.96$32.415$32.89308.5K
Oct 20, 2026$31.46$32.42$31.30$32.27268.11K
Oct 19, 2026$31.68$31.86$31.30$31.52269.95K
Oct 16, 2026$31.12$31.7921$31.07$31.30324.45K
Oct 15, 2026$30.27$31.08$30.19$31.03275.76K
Oct 14, 2026$30.25$30.70$29.76$30.04238.21K
Oct 13, 2026$30.32$30.67$30.10$30.60164.87K
Oct 12, 2026$30.52$30.97$30.1744$30.39151K
Oct 9, 2026$30.78$31.01$30.11$30.63145.6K
Oct 8, 2026$30.60$30.93$30.40$30.68172.01K
Oct 7, 2026$31.45$31.53$30.43$30.73200.54K
Oct 6, 2026$32.17$32.21$31.65$31.83187.74K
Oct 5, 2026$31.51$32.37$31.03$31.92243.68K
Oct 2, 2026$31.80$32.31$31.52$31.63254.95K
Oct 1, 2026$30.59$31.33$30.05$31.29307.42K
Sep 30, 2026$31.34$31.34$30.675$30.77289.32K
Sep 29, 2026$31.65$31.845$30.885$31.26299.86K
Sep 28, 2026$31.25$31.8758$30.80$31.48268.15K
Sep 25, 2026$31.64$31.87$31.235$31.36323.9K
Sep 24, 2026$31.63$32.15$31.38$31.62495.08K

Latest MYE news

The latest Smart Investors Daily articles mentioning MYE.

Stock researchCompany · Overview

MYE research

Overview

Company profile and research snapshot.

Company profile

Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$21.00
Implied upside
—
Analysts
—
MYE recent ratings
DateFirmRatingTarget
Jun 30, 2026KeybancOverweight—
Feb 18, 2026KeybancOverweight—
Jun 13, 2025KeybancOverweight—
Nov 6, 2024KeybancSector Weight—
Oct 9, 2024KeybancOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Is Amgen Stock Worth More Than Its Competitors?

Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. The company ranks second within this group for both sales growth and operating margin. Its valuation tells a different story. Leaving out Merck and Pfizer, which each reported a loss in at least one of their last four quarters, Amgen has the third highest P/E of the four companies that can be compared. So how far apart are what Amgen delivers and what

Yahoo · Oct 13, 2026

What Does Bristol-Myers Squibb Offer That Pfizer Does Not?

Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market exclusivity. Both drugmakers point to 2028 as the year that matters. Pfizer is acquiring drugs and cutting costs to bridge the gap, while Bristol Myers still relies on Eliquis, an older drug that continues to grow. So what did each company tell investors at its latest report about how that replacement is going.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By